Dfuse awarded a 3-year, $5M contract with the FDA to provide E2E platform testing

August 16 2022

Dfuse Technologies, Inc. has been awarded a 3-year, $5M contract with the HHS‘ Food and Drug Administration (FDA) to provide E2E platform testing. The award is a small business set-aside action on the CIO-SP3 SB contract vehicle.

End-to-End Testing (Platform Testing)

The scope of this task order is to advance the development and maturation of the existing testing program in the FDA, Center for Drug Evaluation and Research’s Office of Business Informatics (OBI) to better execute and integrate disparate testing activities in OBI. The testing capability is intended specifically to establish and maintain an end-to-end testing methodology that ensures that all integrated components perform as expected from start to finish. The scope of the testing and evaluation services includes building, maintaining, and supporting a testing bridge between the various development teams (currently known as the Capability and Implementation teams) for enabling improved evaluation services, and test implementation and execution across the IT development life cycle.

Government Customer: Department of Health and Human Services, Food and Drug Administration, Office of Operations